Newer therapies - DiabetesontheNet

This site is intended for healthcare professionals only

Newer therapies

Filter:

The management of hyperglycaemia in people with diabetes and chronic kidney disease: A GPnotebook Shortcut

Glucose-lowering drug indications and dosing recommendations: a GPnotebook quick guide.

Diabetes Distilled: 2019 ADA/EASD consensus update proposes expanded role for GLP-1 RAs in atherosclerotic CVD

What's new in the 2019 update to the ADA/EASD type 2 diabetes consensus guidance?

15th National Conference of the PCDS: Part 1

The key learning points and their application to practice from the broad range of topics presented at the conference.

Editorial: The 2019 ESC/EASD guidelines: Comprehensive and controversial

The broad-ranging recommendations from the ESC and ADA, and the implications for primary care.

Lower blood pressure enhances SGLT2 renoprotection

Researchers wanted to understand the relationship between the renoprotective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors and blood pressure (BP) in patients with low BP. They examined BP and urinary albumin:creatinine ratio data from patients with type 2 diabetes and chronic kidney disease before and after treatment. Lower BP was found to be associated with greater change in urinary albumin:creatinine ratio following treatment with SGLT2 inhibitors. The researchers concluded that stricter BP management is required to enhance the renoprotective effects of SGLT2 inhibitors.

Time-in-range an increasingly important metric

We need to increase our awareness of heart failure in our patients with diabetes

With growing evidence that SGLT2 inhibitors can improve heart failure-related outcomes, Su Down argues the need to increase healthcare professional awareness of heart failure and routinely discuss it with patients.

Oral semaglutide significantly reduces cardiovascular events

An outcome study for oral semaglutide has evaluated the drug’s cardiovascular safety against placebo when added to standard care. Semaglutide is an injectable incretin that has recently become available; oral semaglutide has not yet been approved by the European Medicines Agency. Results showed no significant difference in three-point major adverse cardiac events, but there was a significant reduction in cardiovascular death and all-cause mortality with oral semaglutide.

iLet bionic pancreas improves blood glucose control

SGLT2 inhibitors – moving on with the evidence

An updated review of the benefits and difficulties associated with the use of SGLT2 inhibitors.

Latest news: ADA 2019 special

Stay abreast of the latest news that could impact diabetes nursing. In this issue, we summarise the key presentations from the American Diabetes Association 79^th Scientific Sessions.

Metformin beats lifestyle changes for long-term weight loss

Investigators associated with the Diabetes Prevention Program and its follow-up study used the data gathered to identify reliable predictors of long-term weight loss that could lead to improved weight management. They discovered that in individuals with weight loss of at least 5% after 1 year, those originally assigned to metformin had the greatest weight loss in follow-up years 6 to 15. Older age and the amount of weight initially lost were the most consistent predictors of long-term weight loss maintenance.

Adjunct liraglutide use in people with type 1 diabetes in the St Vincent’s Healthcare Group, Dublin: An Irish perspective

Patricia Harkin and colleagues report their experience with liraglutide as an adjunct to insulin therapy, observing improvements in weight, glycaemic control and insulin requirements.

Latest news

Stay abreast of the latest news that could impact diabetes nursing. May 2019.

How to use GLP-1 receptor agonist therapy safely and effectively

NOTE: An updated version of this guide has been published in February 2023.

CREDENCE trial shows renoprotective effect of canagliflozin

Results of the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial have been published in the New England Journal of Medicine, demonstrating a 30% reduction in renal outcomes with canagliflozin compared with placebo in people with type 2 diabetes and chronic kidney disease (CKD).

Glargine 300 units/mL reduces nocturnal hypoglycaemia in over 65s

Introducing the Primary Care Diabetes Society Clinical Hubs

David Millar-Jones introduces the Primary Care Diabetes Society's new resources to help busy healthcare professionals digest the most relevant advances in diabetes and incorporate them into everyday practice.

Resources

For the latest news and articles

Sign up to all DiabetesontheNet journals

Follow us for all the latest news and updates in diabetes.

Resources

Journals

Useful information

© Copyright Omniamed Communications. All Rights Reserved
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom

;